StockNews.com began coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Stock Up 2.8 %
RedHill Biopharma stock opened at $0.43 on Friday. RedHill Biopharma has a 52 week low of $0.26 and a 52 week high of $3.28. The stock has a 50-day moving average price of $0.51 and a 200 day moving average price of $0.74.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in RedHill Biopharma stock. Sabby Management LLC purchased a new stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 635,006 shares of the biotechnology company’s stock, valued at approximately $324,000. RedHill Biopharma makes up 0.2% of Sabby Management LLC’s portfolio, making the stock its 17th biggest position. Sabby Management LLC owned 5.74% of RedHill Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Read More
- Five stocks we like better than RedHill Biopharma
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 4/22 – 4/26
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks Leading the U.S. Agriculture Comeback
- Canada Bond Market Holiday: How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.